IL276689A - Sustained release formulations of bempedoic acid - Google Patents
Sustained release formulations of bempedoic acidInfo
- Publication number
- IL276689A IL276689A IL276689A IL27668920A IL276689A IL 276689 A IL276689 A IL 276689A IL 276689 A IL276689 A IL 276689A IL 27668920 A IL27668920 A IL 27668920A IL 276689 A IL276689 A IL 276689A
- Authority
- IL
- Israel
- Prior art keywords
- sustained release
- release formulations
- bempedoic acid
- bempedoic
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862710417P | 2018-02-16 | 2018-02-16 | |
| US201862774083P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/018356 WO2019161307A1 (en) | 2018-02-16 | 2019-02-15 | Sustained release formulations of bempedoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL276689A true IL276689A (en) | 2020-09-30 |
Family
ID=65685995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276689A IL276689A (en) | 2018-02-16 | 2020-08-12 | Sustained release formulations of bempedoic acid |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3752133A1 (en) |
| JP (1) | JP2021513987A (en) |
| KR (1) | KR20200123181A (en) |
| CN (1) | CN111971030A (en) |
| AU (1) | AU2019221765A1 (en) |
| BR (1) | BR112020016494A2 (en) |
| CA (1) | CA3091259A1 (en) |
| CL (1) | CL2020002101A1 (en) |
| IL (1) | IL276689A (en) |
| MX (1) | MX2020008527A (en) |
| PH (1) | PH12020551263A1 (en) |
| RU (1) | RU2020129191A (en) |
| SG (1) | SG11202007825XA (en) |
| TW (1) | TW202000191A (en) |
| WO (1) | WO2019161307A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022536979A (en) | 2019-06-21 | 2022-08-22 | エスペリオン・セラピューティクス・インコーポレイテッド | Benpedoic acid in salt form and methods of using same |
| CN111381270B (en) * | 2020-03-06 | 2023-04-18 | 广西田东力源宝科技有限公司 | Method for monitoring fertilizer distribution by utilizing isotope tracing |
| EP4346795A1 (en) | 2021-06-02 | 2024-04-10 | Esperion Therapeutics, Inc. | Compositions containing and therapies using bempedoic acid and tolvaptan |
| KR20240055103A (en) | 2021-09-13 | 2024-04-26 | 신톤 비.브이. | Pharmaceutical compositions of bempedoic acid |
| WO2023093807A1 (en) * | 2021-11-24 | 2023-06-01 | 南京昕瑞再生医药科技有限公司 | Compound and method for treating liver diseases |
| WO2023217694A1 (en) * | 2022-05-09 | 2023-11-16 | Renata Pharmaceutical (Ireland) Ltd | Pharmaceutical composition of bempedoic acid |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US3865108A (en) | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4002173A (en) | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4207893A (en) | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4519801A (en) | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
| US4578075A (en) | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
| US4681583A (en) | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
| US5019397A (en) | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
| US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| MXPA05007674A (en) | 2003-01-23 | 2005-09-22 | Esperion Therapeutics Inc | Hydroxyl compounds and compositions for cholesterol management and related uses. |
| CN101669948A (en) * | 2008-09-11 | 2010-03-17 | 北京科信必成医药科技发展有限公司 | Sustained release tablets of nicotinic acid and lovatatin and preparation method thereof |
| CN103142552A (en) * | 2013-02-22 | 2013-06-12 | 广州科的信医药技术有限公司 | Lovastatin enteric coated sustained-release pellet capsule and preparation method thereof |
| MA41793A (en) * | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | FIXED DOSE ASSOCIATIONS INCLUDING ETC1002 AND ONE OR MORE STATINS TO TREAT OR REDUCE A CARDIOVASCULAR RISK |
| WO2017023165A1 (en) * | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
-
2019
- 2019-02-15 BR BR112020016494-1A patent/BR112020016494A2/en not_active Application Discontinuation
- 2019-02-15 EP EP19709204.2A patent/EP3752133A1/en not_active Withdrawn
- 2019-02-15 JP JP2020543645A patent/JP2021513987A/en active Pending
- 2019-02-15 SG SG11202007825XA patent/SG11202007825XA/en unknown
- 2019-02-15 AU AU2019221765A patent/AU2019221765A1/en not_active Abandoned
- 2019-02-15 CA CA3091259A patent/CA3091259A1/en active Pending
- 2019-02-15 MX MX2020008527A patent/MX2020008527A/en unknown
- 2019-02-15 CN CN201980025286.XA patent/CN111971030A/en active Pending
- 2019-02-15 WO PCT/US2019/018356 patent/WO2019161307A1/en unknown
- 2019-02-15 RU RU2020129191A patent/RU2020129191A/en unknown
- 2019-02-15 KR KR1020207026783A patent/KR20200123181A/en unknown
- 2019-02-18 TW TW108105340A patent/TW202000191A/en unknown
-
2020
- 2020-08-12 IL IL276689A patent/IL276689A/en unknown
- 2020-08-13 CL CL2020002101A patent/CL2020002101A1/en unknown
- 2020-08-17 PH PH12020551263A patent/PH12020551263A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200123181A (en) | 2020-10-28 |
| JP2021513987A (en) | 2021-06-03 |
| SG11202007825XA (en) | 2020-09-29 |
| WO2019161307A1 (en) | 2019-08-22 |
| CN111971030A (en) | 2020-11-20 |
| EP3752133A1 (en) | 2020-12-23 |
| CA3091259A1 (en) | 2019-08-22 |
| PH12020551263A1 (en) | 2021-07-05 |
| CL2020002101A1 (en) | 2021-02-19 |
| RU2020129191A (en) | 2022-03-16 |
| AU2019221765A1 (en) | 2020-09-10 |
| TW202000191A (en) | 2020-01-01 |
| BR112020016494A2 (en) | 2020-12-15 |
| MX2020008527A (en) | 2020-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276689A (en) | Sustained release formulations of bempedoic acid | |
| EP3096759A4 (en) | Modified release formulations of pridopidine | |
| IL304732A (en) | Modified release orally administered amino acid formulations | |
| FI3943070T3 (en) | Long-acting formulations of bedaquiline | |
| ZA201905380B (en) | 1-amino-1-cyclopropanecarboxylic acid hudrochloride formulations | |
| ZA201905379B (en) | 1-amino-1-cyclopropanecaboxylic acid formulations | |
| IL289557A (en) | Sustained release compositions of endoxifen | |
| IL258852A (en) | Sustained release formulations of local anesthetics | |
| IL272857A (en) | Formulations of copanlisib | |
| IL271658B1 (en) | New oral formulations of belinostat | |
| EP3727365A4 (en) | Modified release formulations of flurbiprofen | |
| PT3678644T (en) | Formulations of copanlisib | |
| PT3644970T (en) | New oral formulations of belinostat | |
| EP3731931A4 (en) | Modified release formulations of fesoterodine | |
| PT3943070T (en) | Long-acting formulations of bedaquiline | |
| AU2015903141A0 (en) | Controlled release formulations of paracetamol |